The clinical use of N-terminal-pro brain natriuretic peptide in elderly patients with mental illness

Clinical Biochemistry

Volumn 43, Issue 16-17, 2010, Pages 1282-1286

  Nilsson, Karin ^a   Gustafson, Lars ^a   Hultberg, Björn ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cobalamin; Creatinine; Cystatin c; Folate; Mortality; N terminal pro brain natriuretic peptide psychogeriatric patients; Vascular disease

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; AGING; ARTICLE; COGNITIVE DEFECT; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MINI MENTAL STATE EXAMINATION; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; VASCULAR DISEASE;

AGED; AGED, 80 AND OVER; CEREBROVASCULAR DISORDERS; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS;

EID: 77957376224     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.08.011     Document Type: Article

References (24)

1. Mielke M.M., Zandi P.P. Hematologic risk factors of vascular disease and their relation to dementia. Dem. Geriatr. Cogn. Disord. 2006, 21:335-352.
2. Alagiakrishnan A., McCracen P., Feldman H. Treating vascular risk factors and maintaining vascular health: Is this the way towards successful cognitive ageing and preventing cognitive decline?. Postgrad. Med. J. 2006, 82:101-105.
3. Qui C., De Ronchi D., Fratiglioni L. The epidemiology of the dementias: an update. Curr. Opin. Psychiatry 2007, 20:380-385.
4. Struthers A.D., Davies J. B-type natriuretic peptide: a simple new test to identify coronary artery disease?. Q. J. Med. 2005, 98:765-769.
5. Galasko G.I.W., Lahiri A., Collison P., Barnes S.C., Senior R. What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease?. Eur. Heart J. 2005, 26:2269-2276.
6. Daniels L.B., Maisel A.S. Natriuretic peptides. J. Am. Coll. Cardiol. 2007, 50:2357-2368.
7. Nilsson K., Gustafson L., Hultberg B. Homocysteine, cystatin C and N-terminal-pro brain natriuretic peptide. Vascular risk markers in elderly patients with mental illness. Dem. Geriatr. Cogn. Disord. 2007, 25:88-96.
8. Gunstad J., Poppas A., Smeal S., Paul R.H., Tate D.F., Jefferson A.L., et al. Relation of brain natriuretic peptide levels to cognitive dysfunction in adults >55years of age with cardiovascular disease. Am. J. Cardiol. 2006, 98:538-540.
9. Feola M., Rosso G.L., Peano M., Agostini M., Aspromonte N., Carena G., et al. Correlation between cognitive impairment and prognostic parameters in patients with congestive heart failure. Arch. Med. Res. 2007, 38:234-239.
10. Kondziella D., Göthlin M., Fu M., Zetterberg H., Wallin A. B-type natriuretic peptide plasma levels are elevated in subcortical vascular dementia. NeuroReport 2009, 20:825-827.
11. Nilsson K., Gustafson L., Fäldt R., Andersson A., Brattström L., Lindgren A., et al. Hyperhomocysteinemia-a common finding in a psychogeriatric population. Europ. J. Clin. Invest. 1996, 26:853-859.
12. DSM IV. Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Association, American Psychiatric Association, Washington, DC. 4th ed.
13. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 1999, 56:303-308.
14. Folstein M.F., McHugh P.R. Mini-mental state: a practical method for grading the state of patients for the clinician. J. Psychiatr. Res. 1975, 12:189-198.
15. Brun A. The neuropathology of vascular dementia and its overlap with Alzheimer's disease. Cerebrovascular disease, cognitive impairment and dementia 2004, 103-115. Martin Dunitz, Taylor & Francis Group, Chapter 9. Second edition. J. O'Brien, D. Ames, L. Gustafson, M. Folstein, E. Chiu (Eds.).
16. Skoog I., Lernfelt B., Landahl S., Palmertz B., Andreasson L.A., Nilsson L., et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996, 347:1141-1145.
17. Launer L.J., Ross G.W., Petrovitch H., Masaki K., Foley D., White L.R., et al. Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol. Aging 2000, 21:49-55.
18. Hofman A., Ott A., Breteler M.M., Bots M.L., Slooter A.J., van Harskamp F., et al. Atherosclerosis apolipoprotein E, and prevalence of dementia and Alzheimers disease in the Rotterdam Study. Lancet 1997, 349:151-154.
19. Ott A., Stolk R.P., van Harskamp F., Pols H.A., Hofman A., Breteler M.M. Diabetes mellitus and risk of dementia: the Rotterdam Study. Neurology 1999, 53:1937-1942.
20. Honig L.S., Tang M.X., Albert S., Costa R., Luchsinger J., Manly J., et al. Stroke and the risk of Alzheimers disease. Arch. Neurol. 2003, 60:1707-1712.
21. Rosendorff C., Beeri M.S., Silverman J.M. Cardiovascular risk factors for Alzheimer's disease. Am. J. Geriatr. Cardiol. 2007, 16:143-149.
22. Kalaria R. Similarities between Alzheimer's disease and vascular dementia. J. Neurol. Sci. 2002, 203:29-34.
23. Korczyn A.D. The underdiagnosis of the vascular contribution to dementia. J. Neurol. Sci. 2005, 229-230:3-6.
24. Pantoni L., Garcia J.H. Pathogenesis of leukoaraiosis. Stroke 1997, 28:652-659.